ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lowered its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 2.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 126,717 shares of the biotechnology company’s stock after selling 3,022 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.05% of ADMA Biologics worth $2,533,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ADMA. Bank of Montreal Can boosted its position in ADMA Biologics by 30.6% in the third quarter. Bank of Montreal Can now owns 2,086,322 shares of the biotechnology company’s stock valued at $40,443,000 after buying an additional 489,320 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics in the third quarter valued at $62,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth about $31,000. Penserra Capital Management LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at about $2,350,000. Finally, Algert Global LLC lifted its holdings in shares of ADMA Biologics by 72.8% in the 3rd quarter. Algert Global LLC now owns 204,388 shares of the biotechnology company’s stock valued at $4,086,000 after buying an additional 86,098 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Raymond James lifted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Up 2.6 %

Shares of ADMA opened at $19.82 on Monday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market cap of $4.69 billion, a P/E ratio of 70.79 and a beta of 0.70. The stock’s 50 day moving average is $19.10 and its two-hundred day moving average is $15.76. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the business posted $0.01 earnings per share. Analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.